February 24, 2020
1 min read

Autologous CD8+ T cells Expressing an Anti-BCMA CAR in Patients with Myeloma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Phase 1/phase 2 interventional, open-label study to test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8-positive T cells expressing an anti-BCMA CAR) for eligible patients with active multiple myeloma.